Antibody evolution immunogens
The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).
1. A composition comprising a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 884 or SEQ ID NO: 866 and a carrier.
2. The composition according to claim 1 wherein said composition comprises a purified gp120 HIV-1 envelope protein consisting of all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 884 or SEQ ID NO: 866.
3. A recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 884 or SEQ ID NO: 866.
4. The composition according to claim 1 wherein the recombinant HIV-1 envelope protein is a gp140 HIV-1 envelope protein.
5. The composition according to claim 1 wherein said composition further comprises an adjuvant.
6. A method of inducing an immune response comprising administering to a mammal in need thereof the composition according to claim 1 in an amount sufficient to effect said induction.
7. The method according to claim 6 wherein the HIV-1 envelope protein is a purified gp120 HIV-1 envelope protein consisting of all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 884 or SEQ ID NO: 866 and is administered as a boost in a prime/boost regimen.
8. The method according to claim 7 further comprising administering a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 889 or SEQ ID NO: 871.
9. The method according to claim 7 further comprising administering a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861.
10. The method of claim 9 , wherein the recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861 is administered as a prime in a prime/boost regimen.
11. The method according to claim 7 wherein said composition is administered by injection.
12. The method according to claim 7 wherein said composition is administered intrarectally or vaginally.
13. The method according to claim 7 wherein said mammal is a human.
14. The method of claim 7 further comprising administering a nucleic acid encoding CH505 TF HIV-1 envelope as a prime in a prime/boost regimen.
15. The composition according to claim 1 , wherein said composition comprises the recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 884.
16. The composition according to claim 1 , wherein said composition comprises the recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 866.
17. The composition according to claim 2 , wherein said composition comprises a purified gp120 HIV-1 envelope protein consisting of all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 884.
18. The composition according to claim 2 , wherein said composition comprises a purified gp120 HIV-1 envelope protein consisting of all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 866.
19. The composition according to claim 17 wherein said composition further comprises an adjuvant.
20. The composition according to claim 18 wherein said composition further comprises an adjuvant.
21. A method of inducing an immune response comprising administering to a mammal in need thereof the composition according to claim 19 in an amount sufficient to effect said induction.
22. A method of inducing an immune response comprising administering to a mammal in need thereof the composition according to claim 20 in an amount sufficient to effect said induction.
23. The method of claim 21 further comprising administering a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 889 or SEQ ID NO: 871.
24. The method according to claim 21 further comprising administering a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861.
25. The method of claim 24 , wherein the recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861 is administered as a prime in a prime/boost regimen.
26. The method of claim 22 further comprising administering a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 889 or SEQ ID NO: 871.
27. The method according to claim 22 further comprising administering a recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861.
28. The method of claim 27 , wherein the recombinant HIV-1 envelope protein comprising all consecutive amino acids immediately after the signal peptide in SEQ ID NO: 879 or SEQ ID NO: 861 is administered as a prime in a prime/boost regimen.
29. The method of claim 19 further comprising administering a nucleic acid encoding CH505 TF HIV-1 envelope as a prime in a prime/boost regimen.
30. The method of claim 20 further comprising administering a nucleic acid encoding CH505 TF HIV-1 envelope as a prime in a prime/boost regimen.